Se siguen las Guías en la prevención primaria de MS Concepción Moro.

Presentación del tema: "Se siguen las Guías en la prevención primaria de MS Concepción Moro."— Transcripción de la presentación:

1 Se siguen las Guías en la prevención primaria de MS Concepción Moro

2 Medicina USA 2009 NEJM

3 Muerte Súbita en Cardiopatía Isquémica

4 Estudios randomizados con DAI en Prevención Primaria de MS

5 ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities May 2008

6 Class I Benefit >>> Risk Procedure/ Treatment SHOULD be performed/ administered Class IIa Benefit >> Risk Additional studies with focused objectives needed IT IS REASONABLE to perform procedure/administer treatment Class IIb Benefit ≥ Risk Additional studies with broad objectives needed; Additional registry data would be helpful Procedure/Treatment MAY BE CONSIDERED Class III Risk ≥ Benefit No additional studies needed Procedure/Treatment should NOT be performed/administered SINCE IT IS NOT HELPFUL AND MAY BE HARMFUL Level A: Data derived from multiple randomized clinical trials or meta-analyses Multiple populations evaluated; Level B: Data derived from a single randomized trial or nonrandomized studies Limited populations evaluated Level C: Only consensus of experts opinion, case studies, or standard of care Very limited populations evaluated Applying Classification of Recommendations and Level of Evidence Level of Evidence:

7 ICD therapy is indicated in patients with LVEF less than or equal to 35% due to prior MI who are at least 40 days post-MI and are in NYHA functional Class II or III. ICD therapy is indicated in patients with nonischemic DCM who have an LVEF less than or equal to 35% and who are in NYHA functional Class II or III. ICD therapy is indicated in patients with LV dysfunction due to prior MI who are at least 40 days post-MI, have an LVEF less than or equal to 30%, and are in NYHA functional Class I. ICD therapy is indicated in patients with nonsustained VT due to prior MI, LVEF less than or equal to 40%, and inducible VF or sustained VT at electrophysiological study. All primary SCD prevention ICD recommendations apply only to patients who are receiving optimal medical therapy and have reasonable expectation of survival with good functional capacity for more than 1 year. Implantable Cardioverter-Defibrillators

8 ICD implantation is reasonable for patients with HCM who have 1 or more major † risk factors for SCD. ICD implantation is reasonable for the prevention of SCD in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) who have 1 or more risk factors for SCD. ICD implantation is reasonable to reduce SCD in patients with long-QT syndrome who are experiencing syncope and/or VT while receiving beta blockers. All primary SCD prevention ICD recommendations apply only to patients who are receiving optimal medical therapy and have reasonable expectation of survival with good functional capacity for more than 1 year. † See Section 3.2.4, “Hypertrophic Cardiomyopathy,” in the full-text guidelines for definition of major risk factors. I IIaIIbIII I IIaIIbIII I IIaIIbIII Implantable Cardioverter-Defibrillators

9 ICD implantation is reasonable for nonhospitalized patients awaiting transplantation. ICD implantation is reasonable for patients with Brugada syndrome who have had syncope. ICD implantation is reasonable for patients with Brugada syndrome who have documented VT that has not resulted in cardiac arrest. ICD implantation is reasonable for patients with catecholaminergic polymorphic VT who have syncope and/or documented sustained VT while receiving beta blockers. ICD implantation is reasonable for patients with cardiac sarcoidosis, giant cell myocarditis, or Chagas disease. I IIaIIbIII I IIaIIbIII I IIaIIbIII I IIaIIbIII I IIaIIbIII Implantable Cardioverter-Defibrillators

10 ICD therapy may be considered in patients with nonischemic heart disease who have an LVEF of less than or equal to 35% and who are in NYHA functional Class I. ICD therapy may be considered for patients with long-QT syndrome and risk factors for SCD. ICD therapy may be considered in patients with syncope and advanced structural heart disease in whom thorough invasive and noninvasive investigations have failed to define a cause. ICD therapy may be considered in patients with a familial cardiomyopathy associated with sudden death. ICD therapy may be considered in patients with LV noncompaction. I IIaIIbIII I IIaIIbIII I IIaIIbIII I IIaIIbIII Implantable Cardioverter-Defibrillators

11

12 1.- Alta eficacia en prevención de MS. 2.- Tratamientos combinados: * Bradi-taquiarritmias * Arritmias supra/ventriculares * IC y arritmias ventriculares... 3.- Implantación fácil. Morbilidad 4% 1.- Tx no curativo. 2.- Más del 50% de los pacientes precisan FAA. 3.- Descargas inapropiadas (arritmias supra, interferencias, rotura de cable...) 4.- Vida limitada de cables y batería del generador. 5.- Coste elevado dispositivo Desfibrilador Desfibrilador Automático Implantable

13 Implante DAI en España. Ultima publicación Registro Nacional 2008

14 Implantes DAI /millón habitantes. Datos Europeos

15 Implant rates per million, high power (2006-2007) Source: Eucomed

16 Las guías pueden incumplirse por exceso o por defecto.

17 Variaciones en la determinación FEVI. No existe la misma evidencia del efecto DAI en mujeres. ¿Como valorar el riesgo competitivo entre MS y muerte por ICC ?. ¿ Edad > 75 años ?. Prevención Primaria

18 Myerburg R.NEJM 2008;359:2245 FEVI en Estudios de PP sobre DAI

19 Mortalidad total en el MADIT II Hazard Ratios and 95 Percent Confidence Intervals for Death from Any Cause in the Defibrillator Group vs Conventional Medical Therapy, according to Selected Clinical Characteristics. Moss AJ et al. MADIT II. NEJM 2002;346; 877-883

20 Factores que refuerzan la indicación de DAI

21 Seguimos las Guias. ¿Cual de ellas?. Las variaciones en Implantacion DAI regionales y nacionales se deben a la distinta Interpretación de las Indicaciones de tipo Clase IIB. Se cumplen las guías en algunos puntos por exceso y en otros por defecto. Prevención Primaria

22 Mujer de 45 años, portadora de una mutación en el gen de la desmoplakina. Hermano con MS a los 35 años. Dos miembros en la familia materna con la mutación identificada llevan DAI. Asintomática. ECG anormal con T negativas sobre VI. EV frecuentes en el Holter. No TVs. ECO y RMN normal. Caso clínico Indicación IIb. Evidencia C

23 Varón de 62 años. IM extenso hace 10 años. FEVI <36%. Clase Funcional I. EV frecuentes en Holter con parejas y algunos tripletes. QRS con duración 110 mseg. EEF: TV/FV no inducibles. Caso clínico Indicación IA, Evidencia A, si FEVI <35% y CF II ó FEVI <30% CF I

24 Sí.Antes quisiera consultar otro médico. U d. n e c e s i t a u n D A I. ¿ A l g ú n d e s e o a n t e s d e l i m p l a n t e ?

25 Interpretación variable de las DISTINTAS guías. Unica explicación de las diferencias en Nº Implantes de DAI y de DAI-CRT. Son necesarios más estudios randomizados en diferentes cohortes poblacionales. Los registros no aportan suficiente nivel de evidencia. Son necesarios nuevos marcadores de MS. Prevención Primaria.